AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 92 min read$COO

A $307M tax benefit lifts Cooper Companies (COO) Q3 earnings and fuels a larger share buyback plan

Cooper Companies (COO) reported Q3 2026 revenue of $1.066B, up 1% YoY. GAAP EPS was $2.24, boosted by a $307.2M tax benefit, while non-GAAP EPS rose 4% to $1.15. Free cash flow increased 66% to $273M. The company also announced a larger share buyback plan following a strategic review.

Original reporting
stocktitan.net
Published Sep 9, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$COO
Bullish
high confidence
Mentioned
$COO
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$COOBullishHigh
01

Why it matters

The earnings beat, driven by a sizable tax benefit and robust free cash flow, provides a clear catalyst for short-term price appreciation. The share buyback reinforces shareholder returns, while inventory reductions may temper future growth.

02

Market read

First-report earnings with material numbers and a large tax benefit make this a high‑impact news item for COO and the broader medical device sector.

03

What to watch

Reduced U.S. channel inventory at CooperVision could pressure Q4 results despite current strength.

Relevance 8/10Novelty 8/10Timing: same-day release September 9, 2026

Background

Cooper Companies (Nasdaq: COO) is a global medical device firm with two main segments: CooperSurgical and CooperVision. The Q3 release includes a strategic review completion and an expanded share repurchase authorization.

Company-level read

Ticker impact

$COOBullishHigh confidence
Context

Cooper Companies reported Q3 earnings with a $307M tax benefit, EPS beat and a $339.1M share repurchase, providing fresh material for traders.

Expected impact

Potential 3-5% price rise in the next trading session, with upside bias if buybacks continue.

Evidence & confidence

The disclosed tax benefit and sizable repurchase are new, material facts that directly improve earnings quality and signal confidence from management.

Market effects

Sector

Medical device sector may see modest uplift as Cooper Companies' strong cash generation highlights demand for fertility and vision products.

Regional

U.S. market may benefit from the earnings beat, while UK tax outcome underscores regulatory risk considerations.

Global

Limited to healthcare investors; no broad macro impact.

Counterpoint

What could challenge this read

The tax benefit is a one-time item; future quarters may revert, making the earnings boost unsustainable.

Key entities

  • Executive
    Al White

    President & CEO of Cooper Companies, quoted on earnings and strategic review.

Read at source← All news

Related articles

SEP 10
$AEOHigh

Premarket movers: American Eagle, Shoe Carnival slide following results

U.S. stock futures were mixed ahead of inflation data. American Eagle (AEO) shares fell 11% after weak results and flat margin outlook. Shoe Carnival (SCVL) dropped 23.3% on disappointing Q2 results and lowered outlook. Cooper Companies (COO) tumbled 15.3% after a revenue miss and lowered guidance. Alumis (ALMS) rose 6.3% on positive drug data. Culp (CFI) surged 18.8% on strong Q1 results. Vince Holding (VNCE) gained 5.3% after Q2 results.

investing.com3 min
SEP 10
$COOHighAI 9/10

Why is Cooper Companies stock plunging 15% today?

Cooper Companies (COO) stock fell 15.3% to $53.76 in pre-market trading after reporting fiscal Q3 2026 revenue of $1.07B, missing estimates by $30M. Adjusted EPS of $1.15 beat expectations. The company cut Q4 guidance, citing inventory reduction headwinds. The board decided to retain CooperSurgical after a strategic review. Piper Sandler and Baird downgraded the stock, citing weak growth and margin prospects.

investing.com2 min
SEP 10
$COOMedAI 8/10

Cooper Companies Q3 Results Up, Cuts FY26 View, Retains CooperSurgical, Expands Buyback; Shares Down

CooperCompanies (COO) reported Q3 earnings up but cut its FY26 outlook, citing U.S. channel inventory reductions at CooperVision. The company will retain CooperSurgical and expand its share buyback program to $3B. Shares fell 14.07% in overnight trading. Q4 guidance includes adjusted EPS of $1.05-$1.09 and revenue of $1.057B-$1.080B. FY26 outlook revised to EPS of $4.51-$4.55 and revenue of $4.229B-$4.252B.

rttnews.com2 min
SEP 9
$COOHighAI 8/10

CooperCompanies (NASDAQ:COO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 16.8%

CooperCompanies (COO) reported Q2 CY2026 sales of $1.07B, flat year-on-year and below estimates. Full-year guidance was 1.5% below analysts' expectations. Non-GAAP EPS of $1.15 beat estimates by 2.7%. The stock dropped 16.8% post-earnings. CEO Al White highlighted record free cash flow and growth in fertility but noted inventory reductions impacted results.

financialcontent.com3 min
SEP 9
$COOHighAI 9/10

Why is Cooper Companies stock plunging today?

Cooper Companies (COO) stock fell 15.3% in after-hours trading to $53.80 after reporting fiscal Q3 2026 results and deciding not to sell its CooperSurgical unit. Non-GAAP EPS beat estimates at $1.15, while revenue grew 1% to $1.066 billion. The company issued cautious Q4 guidance and expanded its share repurchase program to $3 billion. The broader market had minimal impact on the stock's decline.

investing.com4 min